Showing 4261-4270 of 7012 results for "".
- Pulmonary Hyalinizing Granuloma and Diagnostic Pitfallshttps://reachmd.com/news/pulmonary-hyalinizing-granuloma-and-diagnostic-pitfalls/2486674/Key Takeaways Incidentally detected pulmonary nodules in a 71-year-old man were described as mimicking metastatic disease on imaging. Surgical pathology identified fibrocollagenous nodules with perivascular inflammatory infiltrates, and immunohistochem
- THRIVE-AA2: Deuruxolitinib Improves Week 24 SALT20 Responsehttps://reachmd.com/news/thrive-aa2-deuruxolitinib-salt20-response/2486601/Key Takeaways THRIVE-AA2 enrolled adults aged 18 to 65 years with severe chronic alopecia areata and assigned 517 participants to two deuruxolitinib dose groups or placebo. Both deuruxolitinib regimens were associated with higher Week 24 SALT20 respons
- Allergan Aesthetics Expands Training Network with New AMI Center in Austinhttps://reachmd.com/news/allergan-aesthetics-expands-training-network-with-new-ami-center-in-austin/2486599/Allergan Aesthetics, an AbbVie company, has announced the opening of a new Allergan Medical Institute (AMI) training center in Austin, Texas, expanding its US educational footprint for aesthetic providers. The facility represents the third AMI Training Center launched in the within the past year,
- Mailed Feedback And Antibiotic Prescribing In Older Adultshttps://reachmd.com/news/mailed-feedback-and-antibiotic-prescribing-in-older-adults/2486591/Key Takeaways: Investigators evaluated mailed feedback to primary care physicians in a pragmatic randomized trial focused on antibiotic prescribing. The reported population was adults aged 65 years and older in outpatient primary care. The stu
- Merz Aesthetics Secures FDA Approval for RADIESSE in Décolleté Treatmenthttps://reachmd.com/news/merz-aesthetics-secures-fda-approval-for-radiesse-in-decollete-treatment/2486550/Merz Aesthetics has received US Food and Drug Administration (FDA) approval for RADIESSE® (calcium hydroxylapatite [CaHA]) for the treatment of moderate to severe wrinkles in the décolleté in adults aged 22 years and older, according to a company announcement. The decision expands the
- MedStar Union Memorial Tops 1,000 Robotic Spine Procedureshttps://reachmd.com/news/medstar-union-memorial-tops-1000-robotic-spine-procedures/2486543/Key points: MedStar Union Memorial Hospital reported completing 1,000 robotic spine procedures Robotic-assisted surgery is used to improve precision, planning, and implant placement The program reflects years of investment in robotic and navig
- Tapinarof Shows Rapid Itch and Skin Improvement in Atopic Dermatitishttps://reachmd.com/news/tapinarof-shows-rapid-itch-and-skin-improvement-in-atopic-dermatitis/2486493/New pooled Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting highlight the rapid onset and consistent efficacy of tapinarof cream 1% (VTAMA; Organon) in patients with moderate-to-severe atopic dermatitis (AD), including children as young as 2 years. Th
- SkinPen Milestone Highlights Growth in Microneedling Demandhttps://reachmd.com/news/skinpen-milestone-highlights-growth-in-microneedling-demand/2486459/Revance announced that it has distributed more than 1 million SkinPen treatment kits nationwide since January 2025, marking a milestone for the company’s microneedling portfolio. The achievement comes approximately 1 year after the launch of SkinPen Precision Elite, the latest iteration of the de
- Nemolizumab Shows Efficacy in Pediatric Atopic Dermatitishttps://reachmd.com/news/nemolizumab-shows-efficacy-in-pediatric-atopic-dermatitis/2486457/Nemolizumab, an IL-31 receptor alpha (IL-31Rα) antagonist, demonstrated favorable pharmacokinetics, sustained efficacy, and a consistent safety profile in children aged 2 to 11 years with moderate-to-severe atopic dermatitis (AD), according to Phase 2 data presented by Linda Stein Gold, MD, at th
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://reachmd.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De